Detection method of gadobutrol injection

By using high-performance liquid chromatography and ultrasonic treatment technology in the detection of gadobutrol injection, the multi-maximal problem of calcium-sodium bolol is solved, the detection sensitivity and accuracy are improved, and the effectiveness of various substances in gadobutrol injection is achieved. Separation and quantification ensure linearity and durability of detection.

CN119023825APending Publication Date: 2024-11-26HAINAN LEVTEC PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310602530.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing gadobutrol injection detection method has low detection sensitivity and cannot effectively separate and accurately detect calcium-sodium piperol, resulting in multimodal phenomena and affecting the accuracy of impurity separation test.

Method used

Using high performance liquid chromatography, C18 reverse anion bonded silica gel chromatography column, ammonium formate buffer solution and acetonitrile as mobile phase, gradient elution was performed, and the test sample solution was sonicated, with the ultrasonic time exceeding 10 minutes. Optimize chromatographic conditions to improve detection accuracy.

Benefits of technology

It effectively solves the multimodal problem of calcium-sodium bolol, improves the sensitivity and accuracy of detection, and ensures the accurate separation and quantification of various substances in gadobutrol injection, with good linearity and strong durability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023825A_ABST
    Figure CN119023825A_ABST
Patent Text Reader

Abstract

The invention relates to a method for detecting gadobutrol injection, which adopts high performance liquid chromatography, and the chromatographic conditions are as follows: a chromatographic column adopts C18 reverse anion bonded silica gel as a filler, an ammonium formate buffer solution as a mobile phase A and acetonitrile as a mobile phase B for gradient elution.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of drug detection, and in particular to a method for detecting gadobutrol injection. Background Art

[0002] Gadobutrol injection was developed and marketed by Bayer. It was first approved for marketing in Switzerland in 1999 and is now available in major European countries such as the United States, Japan, the United Kingdom, and Germany. Gadobutrol injection is used for diagnosis and is only for intravenous administration. It is used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of lesions in various parts of the body (including the brain and spinal cord) and contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body.

[0003] There are three main possible process impurities in gadobutrol: impurity A, impurity B and impurity C, among which impurity B is a degradation impurity. The structural formula is as follows:

[0004]

[0005] Possible impurities of gadobutrol injection include: impurity A and impurity C. Impurity B and the excipient calcium sodium butrol elute at the same position. Impurity B has been indirectly controlled by other means, so it is not necessary to control impurity B in this injection. For the impurities contained in gadobutrol injection, the analysis method of related substances in the import registration standard (JX20140338) uses a charged aerosol detector (CAD). Under the test sample concentration and injection volume of the import registration standard, the detection sensitivity of impurity C is low.

[0006] Therefore, based on the current analytical detection technology, it is particularly important to develop an accurate, efficient and sensitive detection method for gadobutrol injection-related substances. Summary of the invention

[0007] The present invention provides an accurate, efficient and highly sensitive method for detecting related substances of gadobutrol injection: the detection method adopts high performance liquid chromatography, and the chromatographic conditions include: a chromatographic column adopts C18 reverse anionic bonded silica gel as a filler, an ammonium formate buffer solution as a mobile phase A, and acetonitrile as a mobile phase B, and gradient elution is performed to detect the test solution, and the gradient elution procedure is:

[0008]

[0009]

[0010] The test solution is subjected to ultrasonic treatment, and further, the ultrasonic time is 20min to 50min, preferably 40min. Further, the gradient elution procedure is:

[0011]

[0012] Furthermore, the gradient elution procedure is:

[0013]

[0014] Furthermore, the gradient elution procedure is:

[0015]

[0016]

[0017] During the detection of gadobutrol injection, it was found that there was another unknown impurity peak at a retention time of about 22 to 28 minutes (varies with the detection conditions). After experimental analysis, it was inferred that the impurity peak was calcium sodium butrol (see Example 2 for details). The multi-peak problem not only leads to deviations in the detection of calcium sodium butrol, but also may cause other impurity peaks to be covered. The experiment found that in the detection of this product, the detection methods in the prior art could not avoid the phenomenon of multiple peaks of calcium sodium butrol.

[0018] However, the inventors accidentally discovered that if the sample is ultrasonically treated for a period of time before injection, the above-mentioned multi-peak problem will be greatly improved, the multi-peak problem of sodium calcium butrolate will be solved, and the multi-peak problem of sodium calcium butrolate will be avoided, which will bring unexpected effects on the impurity separation test.

[0019] The time of ultrasonic treatment in the present invention is selected from more than 10 minutes, including but not limited to 20 minutes, 25 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes....

[0020] Furthermore, the pH range of the ammonium formate buffer solution is 2.5 to 6.0, preferably 3.6.

[0021] Furthermore, the concentration of the ammonium formate buffer solution is 10 mmoL / L to 20 mmoL / L, preferably 20 mmoL / L.

[0022] Furthermore, the temperature of the sample injection plate is 5°C to 15°C, preferably 10°C.

[0023] In some preferred experimental schemes, the column temperature of the chromatographic column is 40°C to 55°C, preferably 40°C; the flow rate of the mobile phase is 0.8 to 1.2 mL / min, preferably 1 mL / min.

[0024] In the present invention, the injection volume of the HPLC column can be selected within a common range. In some preferred experimental schemes, the injection volume is 20 μL and the test sample concentration is 10 mg / mL.

[0025] In the present invention, the chromatographic column uses C18 reverse anion bonded silica gel as a filler, and the specifications of the chromatographic column are 4.6mm×250mm, 5μm.

[0026] In the present invention, the detector is a charged aerosol detector (CAD).

[0027] Furthermore, atomization temperature: 35°C, frequency: 10 Hz, filtering: 10 s.

[0028] The present invention has the following beneficial effects:

[0029] (1) The present invention uses ultrasound to pre-treat the test solution to change the multi-peak phenomenon of sodium calcium butrolate, avoid misleading it as an impurity peak, and avoid the multi-peak of sodium calcium butrolate bringing unexpected effects during the impurity separation test;

[0030] (2) The detection method of the present invention can effectively separate and accurately test the various substances and their contents in gadobutrol injection, with good peak shape;

[0031] (3) The detection method of the present invention has good linearity. It can be seen from the method verification examples of the present invention that when the impurities are within the range of the quantitative limit to the limit concentration of 200% and the gadobutrol concentration is within the range of 0.05% to 2.0%, the impurities R 2 All are greater than 0.999, with good linearity;

[0032] (4) The detection method of the present invention has good durability and strong durability.

[0033] The following abbreviations have the following meanings:

[0034] CAD stands for charged aerosol detector;

[0035] GDB stands for gadobutrol. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 It is the HPLC chart of Comparative Example 1;

[0037] Figure 2 HPLC diagram of the sensitivity of the quantitative limit solution in Comparative Example 1;

[0038] Figure 3 It is the overlay of the system suitability solution stability of Comparative Example 1;

[0039] Figure 4 It is the HPLC chart of Comparative Example 2;

[0040] Figure 5 It is the HPLC chart of Comparative Example 3;

[0041] Figure 6It is the HPLC chart of Comparative Example 4;

[0042] Figure 7 It is the HPLC chart of Comparative Example 5;

[0043] Figure 8 HPLC diagram of Example 1;

[0044] Fig. 9 HPLC chart of the test solution under the chromatographic conditions in Comparative Example 2 (chromatographic column 3 is selected);

[0045] Fig.10 This is the HPLC graph of the test solution under the chromatographic conditions of Comparative Example 1;

[0046] Fig.11 This is the HPLC chart of the homemade calcium sodium butrol solution under the M01 chromatographic condition in Example 1;

[0047] Fig.12 HPLC graphs of the test solution and calcium sodium butrol solution under the chromatographic conditions of Comparative Example 1;

[0048] Fig.13 This is an overlay of the injection of the original solution of calcium sodium butrol and the test solution under the chromatographic conditions of M01 in Example 2. DETAILED DESCRIPTION

[0049] Comparative Example 1

[0050] 1. Chromatographic conditions

[0051] (1) Chromatographic column: Luna PhenyL-HexyL, 4.6 mm × 250 mm, 3 μm;

[0052] (2) Mobile phase: Mobile phase A: acetonitrile-water (5:995) (pH 3.6±0.1); Mobile phase B: acetonitrile;

[0053] (3) Elution procedure:

[0054]

[0055] (4) Flow rate: 1.0 mL / min;

[0056] (5) Column temperature: 50°C;

[0057] (6) Sample tray temperature: 10°C;

[0058] (7) Sensitivity solution: quantitatively dilute with mobile phase A to prepare a solution containing about 1.25 μg / mL of gadobutrol, with a signal-to-noise ratio of not less than 10; System suitability solution: containing about 2.5 mg / mL of gadobutrol and about 1.25 μg / mL each of impurities A, B, and C;

[0059] (8) Diluent: acetonitrile-water (5:995), pH adjusted to 3.6 with 50% formic acid;

[0060] (9) Detector: CAD.

[0061] 2. Results Analysis

[0062] like Figure 1 and Figure 2 As shown in Figure 1, the detection sensitivity of impurity C is low, with a limit concentration S / N of only 6.0, and the S / N of the sensitivity solution (equivalent to a test sample concentration of 0.05%) is only 9.4, which does not meet the detection sensitivity requirements. At the same time, the stability test results of the system suitability solution after multiple injections (such as Figure 3 As shown in the figure, the retention time of chlorine introduced by the pH regulator hydrochloric acid has been drifting, which is not conducive to the judgment of related substance impurities. Therefore, this method is not suitable for the detection of related substances in gadobutrol injection.

[0063] Comparative Example 2

[0064] 1. Chromatographic conditions

[0065] (1) Chromatographic column:

[0066] 1) Chromatographic column 1: ACE Excel 3Super C18, 4.6×150 mm;

[0067] 2) Column 2: CAPCLL PAK ADME, 4.6×150 mm, 5 μm;

[0068] 3) Column 3: Acclaim Mixed-Mode WAX-1, 4.6 mm × 250 mm, 5 μm;

[0069] (2) Mobile phase: Mobile phase A: formic acid water (pH 3.6); Mobile phase B: acetonitrile;

[0070] (3) Elution procedure:

[0071]

[0072] (4) Flow rate: 1.0 mL / min;

[0073] (5) Column temperature: 50°C;

[0074] (6) Sample pan temperature: 10°C;

[0075] (7) Diluent: water;

[0076] (8) Detector: CAD; atomization temperature: 35°C; frequency: 10 Hz; filtering: 3.6 s;

[0077] (9) Injection volume: 40 μL.

[0078] System suitability solution: containing about 10 mg / mL of gadobutrol and about 5 μg / mL of impurity C. Detection was performed using chromatographic columns 1 to 3 under chromatographic conditions (2) to (9), respectively.

[0079] 2. Results Analysis

[0080] like Figure 4 As shown in the figure, on the ACE ExceL3 Super C18, 4.6×150mm, 3μm column, impurity C was wrapped by the main peak and could not be effectively separated; on the CAPCLL PAK ADME, 4.6×150mm, 5μm column, the main component and impurity C were not baseline separated; on the Acclaim Mixed-Mode WAX-1, 4.6mm×250mm, 5μm column, the separation between the main component and the impurity C of the component to be measured was at least 7.8, and the specificity was the best.

[0081] Comparative Example 3

[0082] 1. Chromatographic conditions

[0083] (1) Column: Acclaim Mixed-Mode WAX-1, 4.6 mm × 250 mm, 5 μm;

[0084] (2) Mobile phase: Mobile phase B: acetonitrile;

[0085] 1) Mobile phase A: 10mmoL / L ammonium formate buffer (pH 2.5);

[0086] 2) Mobile phase A: 10mmoL / L ammonium formate buffer (pH 3.6);

[0087] 3) Mobile phase A: 10mmoL / L ammonium formate buffer (pH 4.5);

[0088] 4) Mobile phase A: 10mmoL / L ammonium formate buffer (pH 6.0);

[0089] (3) Elution procedure:

[0090]

[0091] (4) Flow rate: 1.0 mL / min;

[0092] (5) Column temperature: 40°C;

[0093] (6) Sample tray temperature: 10°C;

[0094] (7) Diluent: water;

[0095] (8) Detector: CAD; atomization temperature: 35°C; frequency: 10 Hz; filtering: 3.6 s;

[0096] (9) Injection volume: 20 μL.

[0097] System suitability solution: containing about 10 mg / mL of gadobutrol, and about 5 μg / mL of impurity B and impurity C. The detection was performed under the conditions of mobile phase A: 1) to 4).

[0098] 2. Results Analysis

[0099] As shown in Table 1 and Figure 5 As shown, when the solutions shown in 1) to 3) are used as mobile phase A, impurities B and C can be effectively separated. Among them, when 10mmoL / L ammonium formate buffer (pH 3.6) is used as mobile phase A, impurities B and C are better separated from adjacent peaks and have a higher response.

[0100] Table 1 System suitability results

[0101]

[0102] Comparative Example 4

[0103] 1. Chromatographic conditions

[0104] (1) Column: Acclaim Mixed-Mode WAX-1, 4.6 mm × 250 mm, 5 μm;

[0105] (2) Mobile phase: Mobile phase B: acetonitrile;

[0106] 1) Mobile phase A: formic acid water (pH 3.6);

[0107] 2) Mobile phase A: 10mmoL / L ammonium formate buffer (pH 3.6);

[0108] 3) Mobile phase A: 20mmoL / L ammonium formate buffer (pH 3.6);

[0109] (3) Elution procedure:

[0110]

[0111]

[0112] (4) Flow rate: 1.0 mL / min;

[0113] (5) Column temperature: 40°C;

[0114] (6) Sample tray temperature: 10°C;

[0115] (7) Detector: CAD; atomization temperature: 35°C; frequency: 10 Hz; filtering: 3.6 s;

[0116] (8) Injection volume: 20 μL;

[0117] System suitability solution: containing about 10 mg / mL of gadobutrol and about 5 μg / mL of impurity C. Gadobutrol injection was tested under the conditions of mobile phase A: 1) to 3).

[0118] 2. Results Analysis

[0119] As shown in Table 2 and Figure 6 As shown, when the solutions shown in 1) to 3) are used as mobile phase A, impurity C can be detected. As the salt concentration increases, the peak of impurity C becomes sharper and the response is significantly improved. When the mobile phase is 20mmoL / L ammonium formate buffer (pH 3.6), the response and separation are optimal.

[0120] Table 2 System suitability results

[0121]

[0122] Comparative Example 5

[0123] 1. Chromatographic conditions

[0124] (1) Column: Acclaim Mixed-Mode WAX-1, 4.6 mm × 250 mm, 5 μm;

[0125] (2) Mobile phase: Mobile phase B: acetonitrile;

[0126] 1) Mobile phase A: 20mmoL ammonium formate buffer (pH 3.6);

[0127] 2) Mobile phase A: 20mmoL / L ammonium formate buffer (pH 4.0);

[0128] (3) Elution procedure:

[0129]

[0130]

[0131] (4) Flow rate: 1.0 mL / min;

[0132] (5) Column temperature: 40°C;

[0133] (6) Sample tray temperature: 10°C;

[0134] (7) Diluent: water;

[0135] (8) Detector: CAD; atomization temperature: 35°C; frequency: 10 Hz; filtering: 3.6 s;

[0136] (9) Injection volume: 20 μL.

[0137] System suitability solution: containing about 10 mg / mL of gadobutrol and about 5 μg / mL of impurity C. Gadobutrol injection was tested under the conditions of mobile phase A: 1) to 2).

[0138] 2. Results Analysis

[0139] As shown in Table 3 and Figure 7 As shown, mobile phase A of 1) to 2) can effectively separate and detect impurity C. When 20mmoL / L ammonium formate buffer (pH 3.6) is used as mobile phase A, the response of impurity C is higher.

[0140] Table 3 System suitability results

[0141]

[0142] Example 1

[0143] 1. Chromatographic conditions

[0144] (1) Column: Acclaim Mixed-Mode WAX-1, 4.6 mm × 250 mm, 5 μm;

[0145] (2) Mobile phase: Mobile phase A: 20 mmol / L ammonium formate buffer (pH adjusted to 3.6 with anhydrous formic acid solution); Mobile phase B: acetonitrile;

[0146] (3) Elution procedure

[0147] 1)M00

[0148]

[0149]

[0150] 2)M01

[0151]

[0152] 3)M02

[0153]

[0154] (4) Flow rate: 1.0 mL / min;

[0155] (5) Column temperature: 40°C;

[0156] (6) Sample tray temperature: 10°C;

[0157] (7) Diluent: water;

[0158] (8) Detector: CAD; atomization temperature: 35°C; frequency: 10 Hz; filtering: 3.6 s;

[0159] (9) Injection volume: 20 μL.

[0160] System suitability solution: Contains about 10 mg / mL of gadobutrol and about 5 μg / mL of impurity C. The test was performed under the conditions of elution programs M00, M01 and M02, respectively.

[0161] 2. Results Analysis

[0162] like Figure 8 As shown, under the gradient elution programs M00, M01 and M02, the peak shapes of each chromatographic peak are good and the impurity C can be effectively separated.

[0163] In the present invention, when optimizing the chromatographic conditions, the unknown impurity peak problem (i.e., the multi-peak problem of sodium calcium butrol) is used as another criterion for judging the gadobutrol detection method, and then the detection method is further optimized, with specific reference to Example 2.

[0164] Example 2

[0165] Using the chromatographic conditions in Comparative Example 2 (selecting chromatographic column 3), sample injection analysis, by Fig. 9 It can be seen that a large unknown peak appears in the test solution (gadobutrol injection) at around 22 minutes; this peak also appears when the chromatographic conditions in Comparative Example 1 are used for testing, such as Fig.10 shown.

[0166] The applicant separately located the impurities, elements or excipients introduced by the raw materials or formulation process, and the impurity peak could not be attributed to impurity A, impurity B, impurity C, sodium, chlorine, calcium or calcium butrobutrol; the main excipients of gadobutrol injection are calcium sodium butrobutrol and tromethamine, and the tromethamine peak can be directly deducted by the positioning solution. Based on the high content of the unknown peak, it is suspected that it should be the calcium sodium butrobutrol peak.

[0167] The applicant prepared the calcium sodium butrol solution by referring to the formulation process, and directly injected the sample under the M01 chromatographic conditions in Example 1. The original solution showed peaks at around 22 minutes and at the calcium butrol peak (3.3 minutes). Fig.11 ), it can be seen that calcium sodium butrol presents a multi-peak phenomenon; the calcium sodium butrol solution was injected under the chromatographic conditions of Comparative Example 1, and it also showed a multi-peak phenomenon, with peaks appearing at the calcium butrol peak positions (8.2min) and 28.1min ( Fig.12), but the detection sensitivity of comparative example 1 is low, so the peak at 28.1min is relatively small. The homemade calcium sodium butrol solution and gadobutrol injection were prepared in the same way as the test sample solution under the chromatographic conditions of M01 in Example 1, and peaks appeared at the calcium sodium butrol position (3.3min) and around 22min ( Fig.13 ), so it was confirmed that this peak was the calcium sodium butrol peak.

[0168] As can be seen from Table 4, the 22-min calcium sodium butrol in the test solution and the calcium sodium butrol solution will gradually decrease to disappear, while the 3.3-min calcium sodium butrol peak area will gradually increase. Since calcium sodium butrol is unstable and a reference substance cannot be obtained, the impurity peak cannot be accurately located and subtracted. However, the 3.3-min peak of calcium sodium butrol and calcium sodium butrol appear at the same position. After converting all the 22-min calcium sodium butrol peaks into 3.3-min peaks, the reference substance of calcium butrol can be used for location subtraction. Therefore, the control of related substances adopts the method of converting all the 22-min calcium sodium butrol peaks into 3.3-min calcium sodium butrol peaks and then performing location subtraction.

[0169] Table 4 Stability of calcium sodium butrol solution

[0170] Time point (h) Calcium sodium butrol peak area (3.3min) Calcium sodium butrol peak area (22min) 0 0.1266 0.0969 1.5 0.3486 0.0101 3.5 0.3742 na 5.5 0.3825 na 9 0.3752 na 11 0.3664 na 13 0.3771 na

[0171] According to the preliminary experiments of the present invention and the experimental results of Example 2, the applicant unexpectedly discovered that the problem of multiple peaks of gadobutrol can be solved by using ultrasound, as specifically referred to in Example 3.

[0172] Example 3

[0173] The test solution (gadobutrol injection) was subjected to different pretreatment processes, i.e., ultrasound or no ultrasound, ultrasound for different time periods, and then injected for detection under the following chromatographic conditions:

[0174] (1) Column: Acclaim Mixed-Mode WAX-1, 4.6 mm × 250 mm, 5 μm;

[0175] (2) Mobile phase: Mobile phase A: 20 mmol / L ammonium formate solution; Mobile phase B: acetonitrile;

[0176] (3) Elution procedure:

[0177]

[0178] (4) Flow rate: 1.0 mL / min;

[0179] (5) Column temperature: 40°C;

[0180] (6) Sample tray temperature: 10°C;

[0181] (7) Diluent: water;

[0182] (8) Detector: CAD; atomization temperature: 35°C; frequency: 10 Hz; filtering: 3.6 s;

[0183] (9) Injection volume: 20 μL;

[0184] (10) Test sample concentration: 10 mg / mL.

[0185] As shown in Table 5, in the untreated test solution, there is an obvious peak at 22 min at 0 h, and the peak area of ​​calcium sodium butrol at 3.3 min increases with the extension of the placement time; with the extension of the placement time, the peak area of ​​calcium sodium butrol at 3.3 min still increases slightly; when ultrasonicated for 40 min, the peak area of ​​calcium sodium butrol at 3.3 min in the test solution tends to be stable, and there is no calcium sodium butrol response peak at 22 min, which does not affect the detection at all. At the same time, under this detection condition, the retention time of chlorine does not drift and is very stable. It can be seen that this method can effectively separate and accurately test the impurities and their contents in gadobutrol injection.

[0186] Table 5 Stability of test solution (calcium sodium butrol peak)

[0187]

[0188]

[0189] Example 4

[0190] The linearity of the detection method provided in Example 3 was investigated. When the concentration of each impurity was within the range of 0.05% to 2.0% of the test sample concentration, each impurity R 2 All of them are greater than 0.999, with good linearity.

[0191] Table 6 Linear correlation data results of gadobutrol and its known impurities

[0192] name Range (μg / mL) Linear equations Linear correlation coefficient A 0.6808~9.0772 y=0.0279x+0.0050 r=0.9987 C 1.4014~11.2110 y=0.0288x-0.0005 r=0.9998 GDB 0.9740~9.7397 y=0.0333x+0.0151 r=0.9992

[0193] Example 5

[0194] 1. Solution stability

[0195] The system suitability solution is stable at 10°C for 115.5 hours; the test solution is stable at 10°C for 110.5 hours.

[0196] Table 7 System suitability solution stability test results

[0197]

[0198]

[0199] Table 8 Test results of the stability of the test solution

[0200] Time (h) GDB-Peak Area Unknown impurity (RRT3.00)-peak area 0 74.1812 0.1342 16 73.6087 0.1364 25.5 74.4322 0.1364 37 73.4953 0.1352 47 72.6772 0.1351 55 73.3699 0.1366 70 73.0643 0.1301 88 73.9035 0.1223 105 73.5842 0.1265 108 73.0989 0.1304 110.5 74.1482 0.1278 RSD% 0.8 3.7

[0201] 2. Chromatographic conditions durability

[0202] The durability of the chromatographic conditions (i.e., initial conditions) of Example 3 was investigated. Under the conditions of flow rate change of ±0.1 mL / min, column temperature change of ±2°C, pH of mobile phase A change of ±0.2, pretreatment time change of ±5 min, different batches of chromatographic columns, and different brands of HPLC, ① blank auxiliary material solution: the chromatogram of the blank auxiliary material solution has no interference peaks at the peak positions of the main peak, impurity A, and impurity C; ② system suitability solution: tromethamine (sodium ion), impurity A, impurity B, gadobutrol, and impurity C peak in sequence, and the separation degree between each component is greater than 1.5; ③ test solution: the separation degree between each component is not less than 1.5; the impurity spectrum in the test sample is consistent, and the absolute difference between the content of each impurity and the total amount of impurities is not greater than 0.02%. The durability is good.

[0203] Table 9 Durability-System Suitability Solution Results

[0204]

[0205]

[0206] It can be seen from the comparative examples and embodiments that the present invention not only solves the problem that impurity C in gadobutrol injection cannot be separated and detected, but also solves the multi-peak problem of calcium sodium butrol, avoiding the unpredictable impact caused by this problem, so that the detection method of the present invention can more effectively separate and accurately test the impurities and their contents in gadobutrol injection.

[0207] The above contents are further detailed descriptions of the present invention in combination with specific implementation methods, and it cannot be determined that the specific implementation methods of the present invention are limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the scope of protection of the present invention.

Claims

1. A method for detecting gadobutrol injection, characterized in that: The detection method adopts high performance liquid chromatography, and the chromatographic conditions include: the chromatographic column uses C18 reverse anion bonded silica gel as a filler, uses ammonium formate buffer solution as mobile phase A, uses acetonitrile as mobile phase B, performs gradient elution, and detects the test solution. The gradient elution program is: The test solution is subjected to ultrasonic treatment, and further, the ultrasonic time is 20 min to 50 min, preferably 40 min.

2. The method for detecting gadobutrol injection according to claim 1, characterized in that: The gradient elution procedure is:

3. The method for detecting gadobutrol injection according to claim 1, characterized in that: The gradient elution procedure is: 。 4. The method for detecting gadobutrol injection according to claim 1, characterized in that: The gradient elution procedure is:

5. The method for detecting gadobutrol injection according to claim 1, characterized in that: The pH range of the ammonium formate buffer solution is 2.5 to 6.0, preferably 3.

6.

6. The method for detecting gadobutrol injection according to claim 1, characterized in that: The concentration of the ammonium formate buffer solution is 10 mmoL / L to 20 mmoL / L, preferably 20 mmoL / L.

7. The method for detecting gadobutrol injection according to claim 1, characterized in that: The sample pan temperature is 5°C to 15°C, preferably 10°C.

8. The method for detecting gadobutrol injection according to claim 1, characterized in that: The column temperature of the chromatographic column is 40-55° C., preferably 40° C., and further, the flow rate of the mobile phase is 0.8-1.2 mL / min, preferably 1 mL / min.

9. The method for detecting gadobutrol injection according to claim 1, characterized in that: The injection volume was 20 μL, and the test sample concentration was 10 mg / mL; the specifications of the chromatographic column were 4.6 mm*250 mm, 5 μm.

10. The method for detecting gadobutrol injection according to claim 1, characterized in that: The detector used was a charged aerosol detector with an atomization temperature of 35°C, a frequency of 10 Hz, and a filter of 3.6 s.